Innovation-led Indian healthcare market to hit $320 bn by FY28: Bain

/2 min read

ADVERTISEMENT

The innovation segment is dominated by pharma services (CDMO, CRO, pharma IT) and health-tech with vaccines and biotech, and med-tech emerging as green shoots
Innovation-led Indian healthcare market to hit $320 bn by FY28: Bain
India's potential as a manufacturing and innovation hub is attracting global players seeking cost-effective solutions and a large talent pool. Credits: Sanjay Rawat

The Indian healthcare market is projected to touch $320 billion in FY28, a 10-12% CAGR growth from $180 billion in FY23, says a report by healthcare fund HealthQuad and global consultancy Bain & Co.

One of the fastest growing segments within the overall healthcare market will be healthcare innovation which will double from the current value of $30 billion to about $60 billion by FY 2028, it says.

The innovation segment is dominated by pharma services (CDMO, CRO, pharma IT) and health-tech with vaccines and biotech, and med-tech emerging as green shoots, the 'Healthcare in Innovation in India' report says.

"From cutting-edge pharma services to disruptive health-tech and med-tech advancements, India's healthcare innovation landscape is experiencing a remarkable transformation. With its focus on innovation, quality, and cost-effectiveness, India's healthcare innovation market is addressing domestic needs and making its mark on the global stage. This $30 billion sector is fuelled by rising investments, supportive government policies, a deepening scientific talent pool and is brimming with potential in nascent fields such as Biotech and MedTech," says Aarthi Rao, partner at Bain & Co.

fortune magazine cover
Fortune India Latest Edition is Out Now!
The Year Of EV Launches

September 2025

2025 is shaping up to be the year of electric car sales. In a first, India’s electric vehicles (EV) industry crossed the sales milestone of 100,000 units in FY25, fuelled by a slew of launches by major players, including Tata Motors, M&M, Ashok Leyland, JSW MG Motor, Hyundai, BMW, and Mercedes-Benz. The issue also looks at the challenges ahead for Tata Sons chairman N. Chandrasekaran in his third term, and India’s possible responses to U.S. president Donald Trump’s 50% tariff on Indian goods. Read these compelling stories in the latest issue of Fortune India.

Read Now

According to the report, the growth will be driven by rising consumerisation of health, reconfigurations to the global healthcare value chain, a deepening of Indian scientific and technological expertise, and regulatory tailwinds.

It notes that post-pandemic, individuals are increasingly proactive in managing their health, driving demand for personalised and accessible solutions. An increased interest in tele-health, wearable devices, and home-based diagnostics were cited as some examples of this trend.

The report also points out that India's potential as a manufacturing and innovation hub is attracting global players seeking cost-effective solutions and a large talent pool. It expects this reconfiguration to foster international collaborations and accelerate innovation within the Indian healthcare ecosystem. On deepening scientific and technological expertise, the report said that talent development and collaborative research initiatives are propelling it. Universities, research institutions, and start-ups are partnering to create a robust innovation ecosystem, fostering ground-breaking discoveries and solutions, it says.

Government initiatives like ease of doing business reforms and open innovation platforms were seen to be removing barriers and streamlining processes.

The report outlines the opportunity in healthcare innovation where companies increasingly leverage emerging technologies to add innovation vectors—including new business models, software-led solutions, and products—that extend beyond more longstanding value engineering considerations.

Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.